Renalytix plc (LSE:RENX) reported unaudited revenue of $1.6 million for the first half of fiscal 2026 and is guiding to full-year revenue of approximately $4 million, representing year-on-year growth of around 33%. The uplift is being driven by faster integration of its kidneyintelX.dkd test into electronic medical record (EMR) systems across U.S. healthcare networks.
The company is preparing a large-scale EMR integration with a major regional health system, which could extend access to more than 40,000 chronic kidney disease patients. Alongside commercial expansion, Renalytix is relocating its laboratory operations to lower its cost base, advancing a real-world evidence programme and progressing its collaboration with Tempus AI, Inc..
Management is also preparing additional clinical data intended to support broader physician adoption and improved reimbursement coverage from payers. These initiatives form part of a strategy to deepen penetration within U.S. healthcare systems and strengthen the long-term commercial case for its technology.
Despite the operational momentum, the company’s outlook remains constrained by continued losses, negative equity and ongoing cash burn. Technical indicators also suggest a weak trend, with the share price trading below key moving averages and momentum signals remaining negative. While recent corporate updates and oversold conditions offer some counterbalance, financial and trend risks continue to weigh on the investment profile.
More about Renalytix
Renalytix is a London- and New York-based developer of artificial intelligence-driven in vitro diagnostics aimed at improving kidney disease management. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic diabetic kidney disease, and is being deployed across major healthcare systems in the United States.
Leave a Reply